Abstract:Several countries have either developed or are developing national induced pluripotent stem cell (iPSC) banks of cell lines derived from donors with HLA homozygous genotypes (two identical haplotypes) prevalent in their local populations to provide immune matched tissues and cells to support regenerative medicine therapies. This haplobank approach relies on knowledge of the HLA genotypes of the population to identify the most beneficial haplotypes for patient coverage, and ultimately identify donors or cord blood units carrying two copies of the target haplotype. A potentially more efficient alternative to a national bank approach is to assess the haplotypes required to provide global patient coverage and to produce a single, global haplobank. Toward that end, we have developed an algorithm to prioritize HLA haplotypes that optimize coverage across the global population. We analyzed data from eighteen countries participating in the Global Alliance for iPS Therapy (GAiT). A representative pool of HLA genotypes, reflecting the HLA of patients, was derived by sampling from each countrys WMDA hematopoietic stem cell donor registry, or surrogate population. An algorithm was created based on HLA-A, -B and -DRB1 haplotype homozygous types with population HLA matching coverage defined by the absence of Host versus Graft (HvG) mismatches at these loci. HLA matching coverage was determined by iteratively selecting HLA haplotypes that provide the largest coverage against patient HLA genotypes sampled from the same population, excluding genotypes compatible with previous iterations. The top 10 haplotypes for each of the 18 countries were identified with patient coverage ranging from 19.5% in Brazil to 63.8% in Japan, with a mean coverage of 33.3%. In a global model, utilizing the 180 most frequent haplotypes across all 18 populations (equivalent to 10 lines per country), the patient coverage ranged from 54.6% in India to 81.7% in Sweden, with a mean of 68.4%. Our findings demonstrate that global collaboration could more than double the potential for patient HLA matching coverage. Interrogation of unrelated hematopoietic stem cell donor registry and cord blood bank HLA data demonstrated that HLA-A, -B, and -DRB1 homozygous donors for the top 180 global haplotypes are widely available. These results show that a globally coordinated strategy for haplobanking would reduce redundancy and allow more patients to be treated with the same investment.

Submission to Stem Cells Reviews and Reports

Current Landscape of iPSC Haplobanks

Inducing Pluripotency for Disease Modeling, Drug Development and Craniofacial Applications.

Advances in Reprogramming of Peripheral Blood Cells to Induced Pluripotent Stem Cells

Exploration of Efficient HLA Haplotypes by Comparing the Proportion of Applicable Populations

Human Amniotic Epithelial Stem Cells: A Promising Seed Cell for Clinical Applications

Autologous Induced Pluripotent Stem Cell–Based Cell Therapies: Promise, Progress, and Challenges

Harnessing Global HLA Data for Enhanced Patient Matching in iPSC Haplobanks

Setting Up a Haplobank: Issues and Solutions

The Immunogenicity and Immune Tolerance of Pluripotent Stem Cell Derivatives

Fit-For-All iPSC-Derived Cell Therapies and Their Evaluation in Humanized Mice With NK Cell Immunity

Current advances in the generation of human iPS cells: implications in cell-based regenerative medicine

Stem Cell Therapy and Immunological Rejection in Animal Models

Bioprocessing considerations for generation of iPSCs intended for clinical application: perspectives from the ISCT Emerging Regenerative Medicine Technology working group

HLA-based banking of induced pluripotent stem cells in Saudi Arabia

Hematopoietic stem cells from induced pluripotent stem cells – considering the role of microRNA as a cell differentiation regulator

Immunogenicity of human embryonic stem cells

Enriching iPSC research diversity: Harnessing human biobank collections for improved ethnic representation

Dysregulation of Immune Tolerance to Autologous iPSCs and Their Differentiated Derivatives

Concise review: Immune recognition of induced pluripotent stem cells.

From banked human cord blood to induced pluripotent stem cells: New opportunities and promise in induced pluripotent stem cell banking (Review)